Phase I Study of Pazopanib in Combination with Weekly Paclitaxel in Patients with Advanced Solid Tumors

PURPOSE. To evaluate the maximum tolerated regimen (MTR), dose-limiting toxicities, and pharmacokinetics of pazopanib, an oral small-molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-Kit, in combination with paclitaxel....

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Tan, Antoinette R., Dowlati, Afshin, Jones, Suzanne F., Infante, Jeffrey R., Nishioka, Jennifer, Fang, Lei, Hodge, Jeffrey P., Gainer, Shelby D., Arumugham, Thangam, Suttle, A. Benjamin, Dar, Mohammed M., Lager, Joanne J., Burris, Howard A.
Format: Artigo
Jezik:Inglês
Izdano: AlphaMed Press 2010
Teme:
Clinical Pharmacology
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3227920/
https://ncbi.nlm.nih.gov/pubmed/21147873
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2010-0095
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items